Therapeutic Potential of Kappa Opioid Agonists.
Tyler C BeckMatthew A HapstackKyle R BeckThomas A DixPublished in: Pharmaceuticals (Basel, Switzerland) (2019)
Many original research articles have been published that describe findings and outline areas for the development of kappa-opioid agonists (KOAs) as novel drugs; however, a single review article that summarizes the broad potential for KOAs in drug development does not exist. It is well-established that KOAs demonstrate efficacy in pain attenuation; however, KOAs also have proven to be beneficial in treating a variety of novel but often overlapping conditions including cardiovascular disease, pruritus, nausea, inflammatory diseases, spinal anesthesia, stroke, hypoxic pulmonary hypertension, multiple sclerosis, addiction, and post-traumatic cartilage degeneration. This article summarizes key findings of KOAs and discusses the untapped therapeutic potential of KOAs in the treatment of many human diseases.
Keyphrases
- chronic pain
- pain management
- nuclear factor
- multiple sclerosis
- cardiovascular disease
- pulmonary hypertension
- endothelial cells
- atrial fibrillation
- spinal cord
- toll like receptor
- type diabetes
- neuropathic pain
- randomized controlled trial
- pulmonary arterial hypertension
- coronary artery
- pluripotent stem cells
- spinal cord injury
- immune response
- coronary artery disease
- inflammatory response
- metabolic syndrome
- blood brain barrier